Improving the diagnosis of eosinophilic asthma (Q38821540)

6 September 2017

1 reference

title

Improving the diagnosis of eosinophilic asthma (English)

1 reference

6 September 2017

1 reference

Hanneke Coumou

1 reference

6 September 2017

Elisabeth H Bel

series ordinal

1 reference

6 September 2017

publication date

14 September 2016

1 reference

Expert Review of Respiratory Medicine

6 September 2017

published in

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

6 September 2017

page(s)

1093-1103

1 reference

Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International

6 September 2017

start time

22 September 2016

1 reference

April 2022 Public Data File from Crossref

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Evolving Concepts of Asthma

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Management of the patient with eosinophilic asthma: a new era begins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Mepolizumab treatment in patients with severe eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Non-eosinophilic asthma: importance and possible mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

A large subgroup of mild-to-moderate asthma is persistently noneosinophilic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Effects of steroid therapy on inflammatory cell subtypes in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Sputum induction in severe asthma by a standardized protocol: predictors of excessive bronchoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Biomarkers in asthmatic patients: Has their time come to direct treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Update on Exhaled Nitric Oxide in Clinical Practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Lebrikizumab Treatment in Adults with Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Clinical and inflammatory features of asthma with dissociation between fractional exhaled nitric oxide and eosinophils in induced sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Treatable traits: toward precision medicine of chronic airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Periostin levels and eosinophilic inflammation in poorly-controlled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Mite allergen-specific IgE is detectable in bronchial secretions of patients with nonatopic asthma and correlates with mucosal expression of periostin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Asthma phenotypes and IgE responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Serum periostin is associated with type 2 immunity in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Stability of inflammatory phenotypes in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Reproducibility of a Single Blood Eosinophil Measurement as a Biomarker in Severe Eosinophilic Asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Domiciliary exhaled nitric oxide and eosinophilic airway inflammation in adults with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Clinical profile of patients with adult-onset eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Exhaled Molecular Fingerprinting in Diagnosis and Monitoring: Validating Volatile Promises.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Breathomics in lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Predicting steroid responsiveness in patients with asthma using exhaled breath profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Application of 'omics technologies to biomarker discovery in inflammatory lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

21 January 2018

The immunology of asthma

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Innate lymphoid cells and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Innate lymphoid cells--a proposal for uniform nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Type 2 innate lymphoid cells: A novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Allergens and the airway epithelium response: gateway to allergic sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Effects of an anti-TSLP antibody on allergen-induced asthmatic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Innate and adaptive immune responses in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Corticosteroid therapy and airflow obstruction influence the bronchial microbiome, which is distinct from that of bronchoalveolar lavage in asthmatic airways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Airway Microbiota in Severe Asthma and Relationship to Asthma Severity and Phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

The A to E of airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

A new initiative on precision medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Chronic diseases like asthma and COPD: do they truly exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Exhaled nitric oxide and blood eosinophilia: Independent markers of preventable risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

Non-invasive phenotyping using exhaled volatile organic compounds in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17476348.2017.1236688

10.1080/17476348.2017.1236688

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference